(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
As tetanus vaccination rates decline, doctors worry about rising case numbers - 2Turkiye’s Erdogan calls Israel’s Somaliland recognition ‘unacceptable’
- 3Allow Innovative Progressions To have a Tremendous Effect
- 4Figure out How to Amplify Innovation and Infotainment Frameworks for Senior Drivers in SUVs
- 5Medical team successfully delivers baby and removes massive tumor
- Israeli strikes in Gaza kill 25 people, Hamas health authority says
- Vote In favor of Your Number one Kind Of Food Conveyance Administration
- The most effective method to Begin Your Excursion in Gold Venture
- These HGTV stars made a pledge to keep their kids off smartphones. Here's how it's going.
- Find the Interesting Universe of Computerized reasoning: the Capability of man-made intelligence
- True serenity: Investigating Emotional well-being and the Advantages of Contemplation
- Administrative building in Sharjah region targeted by Iranian drone, UAE authorities announce
- Manual for 10 Scrumptious Specialty Mixed drinks
- Passover under fire: Israelis balance fatigue with cautious hope after month of war
